Table 1.
Baseline characteristics.
| N = 35 (%) | |
|---|---|
| Age, years | |
| Median (range) | 70 (47-80) |
| <70 | 16 (46%) |
| ≥70 | 19 (54%) |
| Sex | |
| Female | 10 (29%) |
| Male | 25 (71%) |
| ECOG performance status | |
| 0 | 22 (63%) |
| 1 | 13 (37%) |
| Primary tumor site | |
| Gastroesophageal junction | 4 (11%) |
| Stomach | 31 (89%) |
| Histological subtype | |
| Intestinal | 17 (49%) |
| Diffuse | 13 (37%) |
| Mixed | 5 (14%) |
| HER2 status | |
| Negative | 24 (69%) |
| Positive | 9 (26%) |
| Not tested | 2 (6%) |
| UGT1A1 status (*6/*28) | |
| Wild type | 14 (40%) |
| Single heterozygous | 13 (37%) |
| Double variant | 1 (3%) |
| Not tested | 7 (20%) |
| Metastatic site | |
| Lymph node | 23 (66%) |
| Peritoneum | 18 (51%) |
| Liver | 12 (34%) |
| Lung | 2 (6%) |
| Measurable lesion | |
| Present | 27 (77%) |
| Absent | 8 (23%) |
| First-line treatment | |
| S-1 + oxaliplatin | 17 (49%) |
| Capecitabine + oxaliplatin | 7 (20%) |
| FOLFOX | 6 (17%) |
| Nab-paclitaxel + S-1 + oxaliplatin | 1 (3%) |
| Docetaxel + S-1 +CDDP | 1 (3%) |
| S-1 + CDDP | 1 (3%) |
| Capecitabine + CDDP | 1 (3%) |
| S-1 + docetaxel | 1 (3%) |
| Prior trastuzumab | |
| Yes | 9 (26%) |
| No | 26 (74%) |
| Prior ramucirumab | |
| Yes | 0 (0%) |
| No | 35 (100%) |
| Previous gastrectomy | |
| Yes | 8 (23%) |
| No | 27 (77%) |
Data are presented as N (%) or median (range).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; S-1, tegafur, oteracil, and gimeracil; CDDP, cisplatin; FOLFOX, leucovorin, fluorouracil, and oxaliplatin.